Get Direct Meds

Get Direct Meds Helping everyday people unlock lasting weight loss transformation 📉✨

07/31/2025

How the GLP-1 Market Has Evolved in 2025

The GLP-1 market has seen significant changes as these medications have become more mainstream. Initially, high demand led to innovative access solutions including compounding options that made treatment more affordable for many patients. As manufacturers scaled production and supply stabilized, the FDA standardized regulations to ensure consistent quality and safety. Today, patients have multiple pathways to access these medications, including direct manufacturer programs, traditional pharmacy channels, and telehealth services. The market evolution reflects the growing recognition of GLP-1 medications as an important treatment option for weight management.

07/31/2025

What Clinical Trials Actually Show About Weight Loss Results

The STEP trials for semaglutide showed participants lost an average of 14.9% of their body weight over 68 weeks, with 83% losing at least 5% of their weight. The SURMOUNT trials for tirzepatide were even more impressive, with participants losing an average of 20.9% of their body weight over 72 weeks, and 57% losing at least 20% of their weight. These results included lifestyle interventions alongside medication and represent the most significant weight loss outcomes ever achieved with non-surgical treatments, bridging the gap between diet/exercise alone (3-5% loss) and bariatric surgery (20-30% loss).

07/31/2025

The Different Types of GLP-1 Medications Available

Not all GLP-1 medications are the same. Daily injections like liraglutide (Saxenda) show 5-7% average weight loss. Weekly injections are more popular: semaglutide (Wegovy) averages 12-15% weight loss, while tirzepatide (Zepbound) averages 15-18% weight loss and is technically a dual agonist targeting both GLP-1 and GIP receptors. There's also an oral version of semaglutide (Rybelsus) approved for diabetes but not currently at weight-loss doses, as pills have lower absorption rates compared to injections.

07/31/2025

From Diabetes Drug to Weight Loss Treatment - The Evolution

GLP-1 medications weren't originally developed for weight loss. The first GLP-1 drug (Byetta) was approved for Type 2 diabetes in 2005. What researchers noticed was that diabetes patients using these medications were experiencing significant weight loss as a "side effect." This led to dedicated clinical trials specifically for obesity treatment. Liraglutide became the first GLP-1 approved for weight management in 2014, followed by semaglutide (Wegovy) in 2021 and tirzepatide (Zepbound) in 2023, with each generation showing increasingly dramatic weight loss results.

07/31/2025

How GLP-1 Medications Actually Work in Your Body

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in your intestines when you eat. It sends signals to your brain that you're full, slows digestion, and helps regulate blood sugar. GLP-1 medications are synthetic versions of this hormone that last much longer in your system than the natural version. While natural GLP-1 breaks down within minutes, these medications can work for days or even a week, which explains why people often report feeling less hungry and more satisfied with smaller portions.

Address

1065 NE 125th St., Suite 207
North Miami, FL

Website

Alerts

Be the first to know and let us send you an email when Get Direct Meds posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category